- LONDON, October 20, 2015 /PRNewswire/ -- Norgine B.V today announced that it will be presenting the following key data; (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) 1. European Colonoscopy Quality Investigation Group: Improving Standards in Colonoscopy Through a Practice Level Audit Tool. Abstract: UEG15-ABS-3692 2. New Low-Volume Bowel Cleansing Solution (NER1006) vs Trisulphate, Polyethylene Glycol 3350+Ascorbate or Sodium Picosulphate/Magnesium Salt: Three Ongoing Multicentre Randomised Parallel Group Phase III Studies in 1914 Patients Undergoing Colonoscopy. Abstract: 15-ABS-3387 3. Impact of Switching From a Brand to a Generic Macrogol on Prescriptions and Doses for Patients with Chronic Constipation in the UK. Abstract: UEG15-ABS-2167 4. Cost Effectiveness of Rifaximin-α 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in United Kingdom. Abstract: UEG15-ABS-1973 5. Cost Effectiveness of Rifaximin-α 550 mg (XIFAXAN/TARGAXAN) in the Reduction of Recurrence of Overt Hepatic Encephalopathy in Sweden. Abstract: UEG15-ABS-1961 See full release on http://www.norgine.com Contact: Isabelle Jouin, T: +44(0)1895-453643 Charlotte Andrews, T: +44(0)1895-453607 Follow us @norgine